Structure Therapeutics reports significant weight loss from mid-stage GLP-1 pill

Structure Therapeutics said Monday that its daily obesity pill led patients to lose about 16% of their body weight relative to placebo after 44 weeks.

The results of the Phase 2 study could position the company to compete against Eli Lilly and Novo Nordisk in a high-stakes race to develop oral versions of blockbuster GLP-1 injections.

Lilly reported last year that its experimental GLP-1 pill, orforglipron, led to only about 11% weight loss in a 72-week trial. Orforglipron is expected to win U.S. regulatory approval in the coming weeks, while Novo launched an oral version of its drug Wegovy late last year. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In